Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Hisamitsu Pharmaceutical Co's 3-Year Dividend Growth Rate or its related term are showing as below:
FSE:4530'
s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -19.8 Med: 0.8 Max: 26.8
Current: -18.8
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Hisamitsu Pharmaceutical Co was 26.80% per year. The lowest was -19.80% per year. And the median was 0.80% per year.
FSE:4530's 3-Year Dividend Growth Rate is not ranked
in the Drug Manufacturers industry.
Industry Median: 7.7
vs FSE:4530: -18.80
During the past 12 months, Hisamitsu Pharmaceutical Co's average Dividends Per Share Growth Rate was -47.70% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was -18.80% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was -8.20% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was -1.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
During the past 13 years, the highest Dividend Payout Ratio of Hisamitsu Pharmaceutical Co was 0.75. The lowest was 0.17. And the median was 0.37.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
During the past 13 years, the highest Dividend Yield of Hisamitsu Pharmaceutical Co was 2.28%. The lowest was 0.00%. And the median was 1.65%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hisamitsu Pharmaceutical Co 3-Year Dividend Growth Rate Related Terms>
FSE:4530 vs AMPH, ESPR, NIKA: 3-Year Dividend Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co 3-Year Dividend Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's 3-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's 3-Year Dividend Growth Rate falls into.
Hisamitsu Pharmaceutical Co 3-Year Dividend Growth Rate Calculation
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Dividend Growth Rate of -18.80% mean?
Hisamitsu Pharmaceutical Co (FSE:4530) has a 3-Year Dividend Growth Rate of -18.80% as of Feb. 2026. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Hisamitsu Pharmaceutical Co and its competitors.
Is Hisamitsu Pharmaceutical Co's 3-Year Dividend Growth Rate too high?
Hisamitsu Pharmaceutical Co's current 3-Year Dividend Growth Rate is -18.80%. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's 3-Year Dividend Growth Rate compare to AMPH and ESPR?
Hisamitsu Pharmaceutical Co's 3-Year Dividend Growth Rate of -18.80% can be compared against companies in the Drug Manufacturers industry. The industry median 3-Year Dividend Growth Rate is 7.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Drug Manufacturers company?
The median 3-Year Dividend Growth Rate among Drug Manufacturers companies is 7.70, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Hisamitsu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median 3-Year Dividend Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current 3-Year Dividend Growth Rate is -18.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current 3-Year Dividend Growth Rate of -18.80%. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current 3-Year Dividend Growth Rate is -18.80%. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current 3-Year Dividend Growth Rate is -18.80% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
3-Year Dividend Growth Rate: -18.80%
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is a Japanese pharmaceutical company that develops, manufactures, and sells prescription drugs and over-the-counter topical medications. Its best-known consumer brand is Salonpas, a line of pain-relieving patches, creams, gels, sprays, and lotions sold widely in Japan, the United States, and other international markets. The company also markets prescription and medical products, including the Mohrus transdermal patch and other topical analgesic and anti-inflammatory treatments, primarily through its pharmaceutical segment. Hisamitsu's revenue comes from sales of these medical and consumer healthcare products, with a significant and growing share generated outside Japan, particularly in the Americas and Asia. It operates manufacturing and research facilities in Japan and abroad and distributes through pharmacies, drugstores, hospitals, and retail channels. The company continues to expand its transdermal drug delivery platform globally.
89GF Score
Get the complete analysis for FSE:4530
3-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
